DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03841630

CompletedPhase 1

A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants

A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

1

Recruiting sites

—

Enrollment

45

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 19-40•Healthy volunteers

Primary endpoint

•Serious AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03841630
Org study ID17136
Secondary IDJ1I-MC-GZBAEli Lilly and Company

Timeline

Milestones

Study first posted2019-02-15actual
Study start2019-03-13actual
Primary completion2019-07-25actual
Study completion2019-07-25actual
Last update posted2019-08-06actual

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age21 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Overtly healthy male or a female who cannot get pregnant
•Have a body mass index (BMI) between 19 and 40 kilograms per square meter (kg/m²), inclusive, at screening
•Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
•Have veins suitable for ease of blood sampling

Exclusion criteria

•Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
•Have previously completed or withdrawn from this study
•Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking during the inpatient stay in the study
•Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
•Have been treated with weight loss medications within 3 months of screening

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

4 endpoints
Primary/protocol endpoint

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline through final follow-up at approximately Day 43

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Pharmacokinetics: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3437943

Time frame:Baseline through final follow-up at approximately Day 43

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Pharmacokinetics: Maximum Concentration (Cmax) of LY3437943

Time frame:Baseline through final follow-up at approximately Day 43

Cmax

concentration, descriptive

Secondary/protocol endpoint

Pharmacokinetics: Time to Maximum Concentration (Tmax) of LY3437943

Time frame:Baseline through final follow-up at approximately Day 43

Tmax

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.